Mye-EUNITER
 

Umansky, Viktor

Research interests focus on the investigation of immunosuppressive mechanisms and development of innovative immunotherapeutic strategies for human malignant melanoma using in particular transgenic mouse melanoma model. Major current projects include i) investigation of the role of myeloid-derived suppressor cells (MDSC) in chronic inflammation-induced immunosuppression during melanoma progression; ii) development of therapeutic strategies neutralizing MDSC-induced immunosuppression using chemotherapeutic agents and target inhibitors; iii) establishment of reliable markers for MDSC in human melanoma and other human tumors; iv) investigation of MDSC, eosinophils and chronic inflammatory factors as biomarkers for cancer progression and clinical response.

Models available:

  • Ret transgenic mouse model of spontaneous melanoma that closely resembles human melanoma regarding the histology, tumor-associated antigens and clinical behavior.

Cells available:

  • Myeloid-derived suppressor cells, macrophages.

Technology available:

  • Research in mice and man
  • FACS analysis
  • Bio-Plex assay
  • RT-PCR
  • Western Blot
  • Immunohistology
  • Immunofluorescence

Key publications related to Mye-EUNITER:

  1. Jiang, H., Gebhardt, C., Umansky, L., Beckhove, P., Schulze, T.J., Utikal, J., and Umansky, V. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int. J. Cancer, 2014, doi: 10.1002/ijc.29297.

  2. Umansky, V., and Sevko, A. Melanoma-induced immunosuppression and its neutralization. Semin. Cancer Biol., 2012, 22: 319-326.

  3. Meyer, C., Sevko, A., Ramacher, M., Bazhin, A.V., Falk, C.S., Osen, W., Borrello, I., Kato, M., Schadendorf, D., Baniyash, M., and Umansky, V. Chronic inflammation promotes myeloid derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA, 108: 17111-17116, 2011.

  4. Beckhove, P., Feuerer, M., Dolenc, M., Schuetz, F., Choi, C., Sommerfeldt, N., Schwendemann, J., Ehlert, K., Altevogt, P., Bastert, G., Schirrmacher, V., and Umansky, V. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J. Clin. Invest., 114: 67-76, 2004.

  5. Feuerer, M., Beckhove, P., Bai, L., Solomayer, E.-F., Bastert, G., Diehl, I.J., Pedain, C., Oberniedermayr, M., Schirrmacher, V., and Umansky, V. Therapy of human tumors in NOD/SCID mice with patient derived re-activated memory T cells from bone marrow. Nature Med., 7, 452-458, 2001.

Contact details:

Clinical Cooperation Unit Dermato-Oncology (G300)
German Cancer Research Center (DKFZ)
Im Neuenheimer Feld 280
69120 Heidelberg
Germany
Phone: +49 621 383-3773
Fax:      +49 621 383-2163
v.umansky@dkfz.de
www.dkfz.de/en/dermato_onko/index.php